ABIONYX Pharma SA

Informe acción ENXTPA:ABNX

Capitalización de mercado: €43.6m

ABIONYX Pharma Crecimiento futuro

Future controles de criterios 2/6

ABIONYX Pharma's earnings are forecast to decline at 23.4% per annum while its annual revenue is expected to grow at 40.7% per year. EPS is expected to decline by 13.8% per annum.

Información clave

-23.4%

Tasa de crecimiento de los beneficios

-13.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs8.4%
Tasa de crecimiento de los ingresos40.7%
Rentabilidad financiera futuran/a
Cobertura de analistas

Low

Última actualización22 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Does ABIONYX Pharma (EPA:ABNX) Have A Healthy Balance Sheet?

Jun 26
Does ABIONYX Pharma (EPA:ABNX) Have A Healthy Balance Sheet?

Is ABIONYX Pharma (EPA:ABNX) Using Too Much Debt?

Oct 12
Is ABIONYX Pharma (EPA:ABNX) Using Too Much Debt?

Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

Jan 27
Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

Previsiones de crecimiento de beneficios e ingresos

ENXTPA:ABNX - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202612-7-7-71
12/31/20257-9-9-91
12/31/20245-6-6-61
6/30/20245-3-3-3N/A
3/31/20245-3-3-3N/A
12/31/20235-4-4-4N/A
9/30/20235-4N/AN/AN/A
6/30/20235-4-2-2N/A
3/31/20235-4-3-3N/A
12/31/20225-4-4-3N/A
9/30/20224-5N/AN/AN/A
6/30/20223-6-6-6N/A
3/31/20222-6-6-6N/A
12/31/20211-6-7-7N/A
9/30/20210-5N/AN/AN/A
6/30/20210-4-6-5N/A
3/31/20210-3-3-3N/A
12/31/2020N/A-2-1-1N/A
9/30/2020N/A-2-1-1N/A
6/30/2020N/A-200N/A
3/31/2020N/A0-2-2N/A
12/31/2019N/A2-4-4N/A
9/30/201901-5-5N/A
6/30/201900-6-6N/A
3/31/20190-3-6-6N/A
12/31/20180-6-6-6N/A
9/30/20180-7-6-6N/A
6/30/2018N/A-8-7-7N/A
3/31/2018N/A-6N/A-8N/A
12/31/2017N/A-5N/A-9N/A
9/30/2017N/A-8N/A-11N/A
6/30/2017N/A-11N/A-13N/A
3/31/2017N/A-18N/A-16N/A
12/31/2016N/A-25N/A-19N/A
9/30/2016N/A-25N/A-19N/A
6/30/2016N/A-24N/A-19N/A
3/31/2016N/A-20N/A-16N/A
12/31/2015N/A-17N/A-14N/A
9/30/2015N/A-13N/A-11N/A
6/30/2015N/A-10N/A-8N/A
3/31/2015N/A-8N/A-6N/A
12/31/2014N/A-7N/A-3N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: ABNX is forecast to remain unprofitable over the next 3 years.

Beneficios vs. Mercado: ABNX is forecast to remain unprofitable over the next 3 years.

Beneficios de alto crecimiento: ABNX is forecast to remain unprofitable over the next 3 years.

Ingresos vs. Mercado: ABNX's revenue (40.7% per year) is forecast to grow faster than the French market (5.6% per year).

Ingresos de alto crecimiento: ABNX's revenue (40.7% per year) is forecast to grow faster than 20% per year.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: Insufficient data to determine if ABNX's Return on Equity is forecast to be high in 3 years time


Descubre empresas en crecimiento